Abstract. In animals, there is sexual dimorphism of both neurohypophysial peptide secretion in response to stressful stimuli and to the inhibitory effects of opioids. In men, endogenous opioids inhibit the release of oxytocin when AVP secretion is stimulated by insulin-induced hypoglycemia. We have now investigated the role of endogenous opioids in the AVP and oxytocin response to insulin-induced hypoglycemia in women. Twelve subjects, 6 in the follicular and 6 in the luteal phase of the menstrual cycle, were infused on 2 occasions with naloxone (4 mg bolus and 6 mg/h) or saline. Soluble insulin (Human Actrapid\s=r\, 0.15 \g=m\/kg,iv) was given and serial blood samples taken. Blood sugar fell significantly (p<0.05) and similarly in all groups. In the follicular phase hypoglycemia led to a rise in plasma AVP from 1.3 \m=+-\0.2 to 1.8 \ m=+-\ 0.2 pmol/l in the saline-infused subjects (NS), and from 1.0 \m=+-\0.1 to 2.0 \m=+-\0.2 pmol/l in the naloxone-infused (p<0.05). AVP rose similarly from 0.6 \m=+-\0.1 to 1.6 \m=+-\0.5 pmol/l (p<0.05) in the luteal phase controls and from 0.8 \m=+-\0.1 to 1.5 \m=+-\0.3 pmol/l (p<0.05) in naloxone-infused subjects in the luteal phase. There were no significant differences between any of these groups. There were no significant changes in plasma oxytocin in any group. We therefore conclude that in women, unlike men, endogenous opioids do not modulate oxytocin or vasopressin release during insulin-induced hypoglycemia. increased by an opioid antagonist during insulininduced hypoglycemia (7). In women breast stim¬ ulation in the luteal but not the follicular phase of the menstrual cycle stimulates OT secretion (8); and in children, the response of AVP to hypogly¬ cemia is absent before puberty (9). We have now used the same stimulus in women to investigate whether a sex difference exists in the neurohy¬ pophysial response to hypoglycemia, whether the response changes during the menstrual cycle, and whether it is modulated by endogenous opioid peptides.
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Results
All subjects experienced symptomatic neuroglycopenia; some became drowsy and were given dex¬ trose, none was nauseated. Blood pressure fell in all groups during the study, but this fall was only sig¬ nificant in the luteal phase subjects ( Table 1) , heart rate rose significantly and similarly in all groups ( Table 2 ). The blood sugar fell significantly in all groups between time 20 and 30 min after insulin; there was no difference between the groups (Table  3 ). Naloxone infusion alone had no effect on unstimulated AVP or OT levels (Table 4 ). In the fol¬ licular phase there were similar small rises of AVP in saline-and naloxone-infused subjects, although the rise in the saline group failed to achieve statis¬ tical significance. In the luteal phase the AVP rise was also similar in both groups (p<0.05). There was no significant difference between follicular and luteal phase AVP changes, (Fig. 1) . OT levels were unaltered in all groups (Fig. 2 ) in response to in- Points are means ± sem.
sulin. Progesterone levels confirmed subjects were in the luteal phase of the menstrual cycle, salineinfused 31 ±4.5 pmol/1 and naloxone-infused 35±9 pmol/1. 
Discussion
When AVP secretion is stimulated by insulin-in¬ duced hypoglycemia in men OT release is inhibited by endogenous opiod peptides (7) . (11) . Testosterone therefore inhibits OT secretion in response to stress both by an organisational effect in the neonate (possibly on ascending nor-adrenergic pathways (6) (14) , and in male and female insulindependent diabetic patients (15) . In the present study we have not seen OT release to this stimulus. Perhaps the difference between the studies reflect the varying degrees or duration of neuroglycopenia induced (13) . In the present study, hypoglyce¬ mia was more marked in both our current female subjects than in our previously reported findings in men (7) .
Women taking estrogen in the form of the oral contraceptive pill have higher basal OT values, and acute ingestion of estrogen results in an increase in OT levels (16) . Exogenous estrogen would there¬ fore seem to enhance basal OT release, although the evidence that the variation in endogenous es¬ trogens during the menstrual cycle effects OT re¬ lease is conflicting (17, 18) . In our previous studies in males we have used nicotine (19) and insulin induced-hypoglycemia (7) and demonstrated that naloxone increases OT release when AVP is re¬ leased in response to these acute stimuli. In women using breast stimulation and breast feeding to stim¬ ulate OT secretion we found no effect of naloxone (20) . The results of the present study demonstrate that in women in either the follicular or the luteal phase of the menstrual cycle endogenous opioids do not inhibit OT or AVP release during insulininduced hypoglycemia and there was no significant response of AVP to hypoglycemia during the folli¬ cular phase. There does therefore appear to be a sexually dimorphic response of neurohypophysial hormones to hypoglycemia, which in females is dependent on the phase of the menstrual cycle. En¬ dogenous opioid peptides also only seem to be active in the inhibition of hypoglycemia-induced OT secretion in the male.
